Breast Cancer News

Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response

Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response

Existing studies that summarize the risks of breast implants are not adequately powered to detect all harms, alleged authors of a study including nearly 100,000 patient outcomes.

Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers

Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers

Whole-exome sequencing revealed that PALB2, ATM, CHEK2, and MSH6 genes were significantly associated with an increased risk of breast cancer; MSH6, RAD51C, TP53, and ATM were found to be linked to an increased risk of ovarian cancer.

Breast Cancer Subtype May Be Predictive of Ipsilateral Breast Tumor Recurrence

Breast Cancer Subtype May Be Predictive of Ipsilateral Breast Tumor Recurrence

Radiotherapy after surgery may modify ipsilateral breast tumor recurrence risk among different subtypes of breast cancer.

Radiofrequency Ablation Plus Surgery May Improve Tumor Control in Early-Stage Breast Cancer

Radiofrequency Ablation Plus Surgery May Improve Tumor Control in Early-Stage Breast Cancer

Whether radiofrequency ablation is a superior treatment option to lumpectomy requires further investigation.

Religion, Spirituality, May Influence Physical Health Outcomes in Survivors of Breast Cancer

Religion, Spirituality, May Influence Physical Health Outcomes in Survivors of Breast Cancer

The role and impact of religiousness/spirituality in determining physical well-being among survivors of breast cancer is not well understood.

Copy Number Abnormalities May Inform Survival, Drug Resistance

Copy Number Abnormalities May Inform Survival, Drug Resistance

For cancers associated with numerous copy number changes, it is difficult to assign disease classifiers and identify useful targets for drug development.

High-Risk Breast Cancer Patients May Not Be Adherent to Heart Failure Monitoring

High-Risk Breast Cancer Patients May Not Be Adherent to Heart Failure Monitoring

There is a paucity of data regarding the cardiotoxicity and the monitoring adherence habits of patients undergoing treatment with trastuzumab or anthracyclines, commonly used therapies among patients with HER2-positive breast cancer.

Ribociclib FDA-Approved For Additional Indications in HR+, HER2- Advanced Breast Cancer

Ribociclib FDA-Approved For Additional Indications in HR+, HER2- Advanced Breast Cancer

The FDA based its approval on the results of a triplet of phase 3 studies, the MONALEESA-2, MONALEESA-3, and MONALEESA-7.

Aggressive Follow-Up Imaging in Breast Cancer Is Geography-Specific

Aggressive Follow-Up Imaging in Breast Cancer Is Geography-Specific

Variations in the use and frequency of advanced imaging post-surgery in patients with breast cancer were observed across regions of the United States.

Tucatinib May Be A Safe, Novel Treatment for ERBB2/HER2-Positive Breast Cancer

Tucatinib May Be A Safe, Novel Treatment for ERBB2/HER2-Positive Breast Cancer

For this phase 1b study, researchers enrolled 57 patients with ERBB2/HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.

Adding Ovarian Suppression May Improve Survival Outcomes in Premenopausal Breast Cancer

Adding Ovarian Suppression May Improve Survival Outcomes in Premenopausal Breast Cancer

Updated results of the SOFT and TEXT trial suggest that adding ovarian suppression to exemestane or tamoxifen could improve survival outcomes.

Trastuzumab Retreatment May Be Safe and Effective in Breast Cancer Recurrence

Trastuzumab Retreatment May Be Safe and Effective in Breast Cancer Recurrence

The effectiveness of trastuzumab in retreating patients with recurrence who received it during perioperative therapy is the focus of a new study.

Do the Risks of Direct-to-Consumer Testing Outweigh the Benefits?

Do the Risks of Direct-to-Consumer Testing Outweigh the Benefits?

There are benefits and drawbacks to the public availability to DTC mutation tests.

Endocrine Therapy Alone Is Not Inferior to Chemoendocrine Therapy in Breast Cancer With Oncotype DX Scores Between 11 and 26

Endocrine Therapy Alone Is Not Inferior to Chemoendocrine Therapy in Breast Cancer With Oncotype DX Scores Between 11 and 26

The effect of combination chemotherapy and endocrine therapy has not been fully clarified among patients with Oncotype DX recurrence scores 11-25.

SANDPIPER: First Trial to Show Modest Benefit of Taselisib in Postmenopausal Women With ER+/HER- Advanced Breast Cancer

SANDPIPER: First Trial to Show Modest Benefit of Taselisib in Postmenopausal Women With ER+/HER- Advanced Breast Cancer

Despite modest improvements in progression-free survival, patients experienced considerable side effects with the addition of taselisib.

PALOMA 3: Elucidating Resistance Mechanisms to Palbociclib and Fulvestrant

PALOMA 3: Elucidating Resistance Mechanisms to Palbociclib and Fulvestrant

It is important to understand mechanisms of resistance with these inhibitors to determine future treatment strategies.

MONALEESA 3: Ribociclib Provides Significant PFS in Postmenopausal Women With ER+/HER- Advanced Breast Cancer Regardless of Prior Endocrine Therapy

MONALEESA 3: Ribociclib Provides Significant PFS in Postmenopausal Women With ER+/HER- Advanced Breast Cancer Regardless of Prior Endocrine Therapy

With a greater than 40% decreased risk for disease progression, the combination of ribociclib and fulvestrant was significantly better than that of placebo and fulvestrant for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer.

First-in-Class ICOS Agonist Alone or In Combination May Be Effective For Advanced Cancer

First-in-Class ICOS Agonist Alone or In Combination May Be Effective For Advanced Cancer

Researchers assigned patients with various types of relapsed/refractory cancer to receive escalating doses of JTX-2011 alone or plus nivolumab.

Pertuzumab, Trastuzumab, Capecitabine May Prolong Overall Survival in HER2-Positive Breast Cancer

Pertuzumab, Trastuzumab, Capecitabine May Prolong Overall Survival in HER2-Positive Breast Cancer

Although progression-free survival was not significantly increased, long-term overall survival may be improved with pertuzumab.

Mentally, Physically Demanding Jobs May Predict Unemployment After Breast Cancer Surgery

Mentally, Physically Demanding Jobs May Predict Unemployment After Breast Cancer Surgery

Understanding various factors associated with unemployment may help to guide breast cancer management to increase the rate of returning to work.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs